Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
Panagiotis Baliakas
(1)
,
Andreas Agathangelidis
(2, 3)
,
Anastasia C Hadzidimitriou
(1)
,
Lesley-Ann Sutton
(1)
,
Eva Minga
(4)
,
Athina Tsanousa
(5)
,
Lydia Scarfò
(3)
,
Zadie Davis
,
Xiao-Jie Yan
(6)
,
Tait Shanafelt
(7)
,
Karla Plevova
(8, 9, 10)
,
Yorick Sandberg
(11)
,
Fie Juhl Vojdeman
(12)
,
Myriam Boudjogra
(13)
,
Tatiana Tzenou
(14)
,
Maria Chatzouli
(15)
,
Charles Chu
(6)
,
Silvio Veronese
,
Anne Gardiner
,
Larry Mansouri
(1)
,
Karin Ekström Smedby
(16)
,
Lone Bredo Pedersen
(12)
,
Denis Moreno
(17)
,
Kirsten van Lom
(11)
,
Véronique Giudicelli
(17)
,
Hana Skuhrova Francova
(10)
,
Florence Nguyen-Khac
(18, 19)
,
Panagiotis Panagiotidis
(14)
,
Gunnar Juliusson
(20)
,
Lefteris Angelis
(5)
,
Achilles Anagnostopoulos
(21)
,
Marie-Paule Lefranc
(17)
,
Monica Facco
(22)
,
Livio Trentin
(22)
,
Mark Catherwood
(23)
,
Marco Montillo
(24)
,
Christian Geisler
(12)
,
Anton Langerak
(11)
,
Sarka Pospisilova
(9)
,
Nicholas Chiorazzi
(6)
,
David Oscier
,
Diane Jelinek
(7)
,
Nikos Darzentas
(8)
,
Chrysoula Belessi
(25)
,
Frederic Davi
(13)
,
Paolo Ghia
(2, 3)
,
Richard Rosenquist
(26, 16)
,
Kostas Stamatopoulos
(16, 4)
1
Uppsala Universitet [Uppsala]
2 IRCCS San Raffaele Pisana - Istituto di Ricovero e Cura a Carattere Scientifico
3 UniSR - Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie]
4 CERTH - Centre for Research and Technology Hellas
5 Aristotle University of Thessaloniki
6 The Feinstein Institute for Medical Research
7 Mayo Clinic [Rochester]
8 CEITEC MU - Central European Institute of Technology [Brno]
9 MUNI - Masaryk University [Brno]
10 University Hospital Brno
11 Erasmus MC - Erasmus University Medical Center [Rotterdam]
12 Rigshospitalet [Copenhagen]
13 CHU Pitié-Salpêtrière [AP-HP]
14 University of Athens Medical School [Athens]
15 University of Piraeus
16 Karolinska Institutet [Stockholm]
17 IGH - Institut de génétique humaine
18 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
19 UPMC - Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie
20 Skane University Hospital [Lund]
21 General Hospital of Thessaloniki George Papanikolaou
22 Unipd - Università degli Studi di Padova = University of Padua
23 Belfast City Hospital
24 Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
25 "IASO" General Hospital of Athens
26 Uppsala University
2 IRCCS San Raffaele Pisana - Istituto di Ricovero e Cura a Carattere Scientifico
3 UniSR - Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie]
4 CERTH - Centre for Research and Technology Hellas
5 Aristotle University of Thessaloniki
6 The Feinstein Institute for Medical Research
7 Mayo Clinic [Rochester]
8 CEITEC MU - Central European Institute of Technology [Brno]
9 MUNI - Masaryk University [Brno]
10 University Hospital Brno
11 Erasmus MC - Erasmus University Medical Center [Rotterdam]
12 Rigshospitalet [Copenhagen]
13 CHU Pitié-Salpêtrière [AP-HP]
14 University of Athens Medical School [Athens]
15 University of Piraeus
16 Karolinska Institutet [Stockholm]
17 IGH - Institut de génétique humaine
18 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
19 UPMC - Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie
20 Skane University Hospital [Lund]
21 General Hospital of Thessaloniki George Papanikolaou
22 Unipd - Università degli Studi di Padova = University of Padua
23 Belfast City Hospital
24 Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
25 "IASO" General Hospital of Athens
26 Uppsala University
Panagiotis Baliakas
- Fonction : Auteur
- PersonId : 1216297
- ORCID : 0000-0002-5634-7156
Zadie Davis
- Fonction : Auteur
- PersonId : 1216296
- ORCID : 0000-0001-6959-4853
Xiao-Jie Yan
- Fonction : Auteur
- PersonId : 1322981
- ORCID : 0000-0002-3717-5803
Karla Plevova
- Fonction : Auteur
- PersonId : 1322980
- ORCID : 0000-0002-6148-8877
Silvio Veronese
- Fonction : Auteur
- PersonId : 1322987
- ORCID : 0000-0002-5280-3740
Anne Gardiner
- Fonction : Auteur
Véronique Giudicelli
- Fonction : Auteur
- PersonId : 1197166
- IdHAL : veronique-giudicelli
- ORCID : 0000-0002-2258-468X
- IdRef : 224422596
Florence Nguyen-Khac
- Fonction : Auteur
- PersonId : 1218304
- ORCID : 0000-0003-3107-6668
Achilles Anagnostopoulos
- Fonction : Auteur
- PersonId : 1322991
- ORCID : 0000-0003-4384-9031
Marie-Paule Lefranc
- Fonction : Auteur
- PersonId : 1253455
- ORCID : 0000-0003-0116-9353
- IdRef : 096991046
Monica Facco
- Fonction : Auteur
- PersonId : 1322983
- ORCID : 0000-0003-0100-5789
Livio Trentin
- Fonction : Auteur
- PersonId : 1322990
- ORCID : 0000-0003-1222-6149
Anton Langerak
- Fonction : Auteur
- PersonId : 784443
- ORCID : 0000-0002-2078-3220
Sarka Pospisilova
- Fonction : Auteur
- PersonId : 1322992
- ORCID : 0000-0001-7136-2680
David Oscier
- Fonction : Auteur
Frederic Davi
- Fonction : Auteur
- PersonId : 1239877
- ORCID : 0000-0002-3764-063X
Paolo Ghia
- Fonction : Auteur
- PersonId : 1216309
- ORCID : 0000-0003-3750-7342
Richard Rosenquist
- Fonction : Auteur
- PersonId : 1216311
- ORCID : 0000-0002-0211-8788
Kostas Stamatopoulos
- Fonction : Auteur
- PersonId : 1216310
- ORCID : 0000-0001-8529-640X
Résumé
An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non–subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non–subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non–subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non–subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
Origine : Fichiers éditeurs autorisés sur une archive ouverte